
Mattias F Lindberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7053724/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. Nature Communications, 2017, 8, 707.	12.8	123
2	HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy–Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice. Cancer Research, 2019, 79, 899-904.	0.9	84
3	A retro-inverso cell-penetrating peptide for siRNA delivery. Journal of Nanobiotechnology, 2017, 15, 34.	9.1	55
4	The gene transfection properties of a lipophosphoramidate derivative with two phytanyl chains. Biomaterials, 2012, 33, 6240-6253.	11.4	40
5	Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFN1 ³ Signaling. Cancer Research, 2017, 77, 4562-4566.	0.9	39
6	A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma. Cell Death and Disease, 2018, 9, 810.	6.3	38
7	Optimisation of vectorisation property: A comparative study for a secondary amphipathic peptide. International Journal of Pharmaceutics, 2016, 509, 71-84.	5.2	31
8	Efficient inÂvivo transfection and safety profile of a CpG-free and codon optimized luciferase plasmid using a cationic lipophosphoramidate in a multiple intravenous administration procedure. Biomaterials, 2015, 59, 1-11.	11.4	30
9	Lipothiophosphoramidates for gene delivery: critical role of the cationic polar headgroup. Organic and Biomolecular Chemistry, 2012, 10, 2051.	2.8	20
10	BET bromodomain inhibitors synergize with ATR inhibitors in melanoma. Cell Death and Disease, 2017, 8, e2982-e2982.	6.3	17
11	Mutational Signature and Transcriptomic Classification Analyses as the Decisive Diagnostic Tools for a Cancer of Unknown Primary. JCO Precision Oncology, 2018, 2, 1-25.	3.0	10
12	Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma. Melanoma Research, 2022, 32, 241-248.	1.2	9
13	Small molecule inhibitors and a kinase-dead expressing mouse model demonstrate that the kinase activity of Chk1 is essential for mouse embryos and cancer cells. Life Science Alliance, 2020, 3, e202000671.	2.8	4